dm+d

Unassigned

New Medicines

Severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy

Information

New molecular entity
Soligenix
Soligenix

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Immunomodulator: a synthetic 5-amino acid peptide modulating the regulatory protein p62 (sequestosome-1; SQSTM1), thus enhancing activity of the innate immune system; modulates inflammation healing.
Oral mucositis affects almost all patients receiving radiotherapy for head and neck cancer, with or without chemotherapy, and for some it is the most distressing part of their treatment [3]. If severe, it causes inability to eat or drink, leading to the need for tube feeding, and it predisposes to infection that can progress to sepsis [4].
Severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy
Intravenous

Further information

Yes